$20.53
-0.07[-0.34%]
At close: May 28
$20.53
0[0.00%]
After Hours: 4:02PM EDT
GeneDx Hldgs
(NASDAQ:WGS)GeneDx Hldgs Stock (NASDAQ:WGS), Analyst Ratings, Price Targets, Predictions
GeneDx Holdings Corp has a consensus price target of $18, established from looking at the 9 latest analyst ratings. The last 3 analyst ratings were released from TD Cowen, BTIG, and BTIG on April 30, 2024, April 30, 2024, and April 22, 2024. With an average price target of $19.33 between TD Cowen, BTIG, and BTIG, there's an implied -5.83% downside for GeneDx Holdings Corp from these 3 analyst ratings.
Analyst Firms Making Recommendations1
TD Cowen
BTIG
Goldman Sachs
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for GeneDx Hldgs
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/30/2024 | Buy Now | 16.9% | TD Cowen | Dan Brennan | $14 → $24 | Maintains | Buy | Get Alert |
| 04/30/2024 | Buy Now | -7.45% | BTIG | Mark Massaro | $15 → $19 | Maintains | Buy | Get Alert |
| 04/22/2024 | Buy Now | -26.94% | BTIG | Mark Massaro | $11 → $15 | Maintains | Buy | Get Alert |
| 04/15/2024 | Buy Now | -46.42% | Goldman Sachs | Matthew Sykes | $6 → $11 | Maintains | Neutral | Get Alert |
| 11/01/2023 | Buy Now | -70.77% | Goldman Sachs | Matthew Sykes | $7 → $6 | Maintains | Neutral | Get Alert |
| 08/09/2023 | Buy Now | -65.9% | Goldman Sachs | Matthew Sykes | $8 → $7 | Maintains | Neutral | Get Alert |
| 07/24/2023 | Buy Now | -61.03% | Goldman Sachs | Matthew Sykes | $9 → $8 | Maintains | Neutral | Get Alert |
| 07/21/2023 | Buy Now | -61.03% | Goldman Sachs | Matthew Sykes | $9 → $8 | Maintains | Neutral | Get Alert |
| 05/15/2023 | Buy Now | -56.16% | Goldman Sachs | Matthew Sykes | $33 → $9 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for GeneDx Hldgs (WGS)?
The latest price target for GeneDx Hldgs (NASDAQ: WGS) was reported by TD Cowen on April 30, 2024. The analyst firm set a price target for $24.00 expecting WGS to rise to within 12 months (a possible 16.90% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for GeneDx Hldgs (WGS)?
The latest analyst rating for GeneDx Hldgs (NASDAQ: WGS) was provided by TD Cowen, and GeneDx Hldgs maintained their buy rating.
When was the last upgrade for GeneDx Hldgs (WGS)?
There is no last upgrade for GeneDx Hldgs.
When was the last downgrade for GeneDx Hldgs (WGS)?
There is no last downgrade for GeneDx Hldgs.
When is the next analyst rating going to be posted or updated for GeneDx Hldgs (WGS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GeneDx Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GeneDx Hldgs was filed on April 30, 2024 so you should expect the next rating to be made available sometime around April 30, 2025.
Is the Analyst Rating GeneDx Hldgs (WGS) correct?
While ratings are subjective and will change, the latest GeneDx Hldgs (WGS) rating was a maintained with a price target of $14.00 to $24.00. The current price GeneDx Hldgs (WGS) is trading at is $20.53, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.